UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 923

Sortiert nach

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Haematologica (Roma), 2016-07, Vol.101 (7), p.803

2016

Volltextzugriff (PDF)

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

Haematologica (Roma), 2019-02, Vol.104 (2), p.e68

2019

Volltextzugriff (PDF)

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)

Neuro-oncology (Charlottesville, Va.), 2021-07, Vol.23 (7), p.1056-1071

2021

Volltextzugriff (PDF)

Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells

Blood, 2021-01, Vol.137 (2), p.203-215

2021

Volltextzugriff (PDF)

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies

British journal of dermatology (1951), 2024-03, Vol.190 (4), p.559-564

2024

Volltextzugriff (PDF)

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

Journal of hematology and oncology, 2021-09, Vol.14 (1), p.1-140, Article 140

2021

Volltextzugriff (PDF)

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma

BMC cancer, 2022-09, Vol.22 (1), p.971-9, Article 971

2022

Volltextzugriff (PDF)

Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis

Hematological oncology, 2019-12, Vol.37 (5), p.548-557

2019

Volltextzugriff (PDF)

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event

Blood, 2015-12, Vol.126 (25), p.2665-2675

2015

Volltextzugriff (PDF)

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Bone marrow transplantation (Basingstoke), 2020-05, Vol.55 (5), p.884-890

2020

Volltextzugriff (PDF)

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

Experimental hematology & oncology, 2022-03, Vol.11 (1), p.17-17, Article 17

2022

Volltextzugriff (PDF)

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK

Health science reports, 2024-01, Vol.7 (1), p.e1749-n/a

2024

Volltextzugriff (PDF)

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Rheumatic & musculoskeletal diseases open, 2024-03, Vol.10 (1), p.e003980

2024

Volltextzugriff (PDF)

Refining CNS relapse risk in DLBCL: easy as ABC?

Blood, 2019-02, Vol.133 (9), p.886-888

Fox, Christopher P.

2019

Volltextzugriff (PDF)

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy

Journal of personalized medicine, 2023-07, Vol.13 (7), p.1182

2023

Volltextzugriff (PDF)

The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper

British journal of haematology, 2020-09, Vol.190 (5), p.708-714

2020

Volltextzugriff (PDF)

Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease

Frontiers in immunology, 2019-10, Vol.10, p.2489-2489

2019

Volltextzugriff (PDF)

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up

HemaSphere, 2024-06, Vol.8 (6), p.e89-n/a

2024

Volltextzugriff (PDF)

Guidelines for the diagnosis and management of primary central nervous system diffuse large B‐cell lymphoma

British journal of haematology, 2019-02, Vol.184 (3), p.348-363

2019

Volltextzugriff (PDF)

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

Therapeutic advances in hematology, 2023-01, Vol.14, p.20406207231173489-20406207231173489

2023

Volltextzugriff (PDF)

Management of secondary central nervous system lymphoma

British journal of haematology, 2023-01, Vol.200 (2), p.160-169

2023

Volltextzugriff (PDF)

Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper

British journal of haematology, 2024-08

2024

Volltextzugriff (PDF)

1 – 25 von 923

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR Complete Journals

ThemaAged, 80 And Over

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(871)
Mit Volltextzugriff
(809)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(676)
Life Sciences & Biomedicine
(570)
Humans
(466)
Male
(286)
Female
(276)
Middle Aged
(174)
Aged
(162)
Adult
(124)
Biological And Medical Sciences
(120)
Medical Sciences
(106)
Cardiovascular System & Cardiology
(100)
Neurosciences & Neurology
(88)
Treatment Outcome
(88)
Cardiac & Cardiovascular Systems
(87)
Hematology
(79)
Animals
(74)
General & Internal Medicine
(73)
Physical Sciences
(70)
Risk Factors
(69)
Surgery
(62)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(60)
Circulation
(30)
British Journal Of Haematology
(23)
Journal Of The American College Of Cardiology
(22)
The Journal Of Trauma And Acute Care Surgery
(21)
The American Heart Journal
(15)
Plos One
(14)
Nature
(12)
The Astrophysical Journal
(12)
The New England Journal Of Medicine
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)

Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma

Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Refining CNS relapse risk in DLBCL: easy as ABC?

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy

The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper

Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up

Guidelines for the diagnosis and management of primary central nervous system diffuse large B‐cell lymphoma

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

Management of secondary central nervous system lymphoma

Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper

Aktive Filter

Suchergebnisse filtern